Template:Company
What They Do[edit]
Cell therapy for children with osteogenesis imperfecta (genetic bone disease / brittle bone disease).
Funding[edit]
€3.1 million additional funding (November 2025).[1]
Traction[edit]
Strategic manufacturing agreement with RoslinCT for cell therapy production.[2]
See Also[edit]
- ↑ EU-Startups (Nov 3, 2025): "In bid to improve outcomes for children with genetic bone disease, Swedish startup BOOST Pharma raises additional €3.1 million"
- ↑ BioSpace (2025): "RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement"
